Delivery Order 75F40123D00039-75F40123F19001
Award Date 9/27/23
Potential Completion Date 3/29/26
Potential Value $3.9M
Federal Agency
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Calverton, MD 20705, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This firm fixed-price delivery order was awarded by the Department of Health and Human Services (HHS) Food and Drug Administration (FDA) to the Lovelace Biomedical Research Institute, a not-for-profit contract research organization. The $2,472,244.00 contract is for the evaluation of e-cigarette aerosol in in vivo nonclinical models and was issued under the In Vivo Toxicology of Tobacco 2015-2020 indefinite delivery, indefinite quantity (IDIQ) contract. Lovelace Biomedical Research Institute has...
- This is a $1,251,731.00 firm fixed-price delivery order contract awarded by the Food and Drug Administration (FDA) to Lovelace Biomedical Research Institute, a not-for-profit preclinical contract research organization. The contract, which has no set-aside designation, is part of Task Order 2 under a larger contract vehicle and is focused on examining the influence of synthetic cooling agents on cigarette sensory and subjective effects, as well as use behavior. Lovelace Biomedical Research...
- This is a firm fixed-price delivery order issued by the Department of Health and Human Services Food and Drug Administration under the In Vivo Toxicology of Tobacco 2015-2020 indefinite delivery/indefinite quantity (IDIQ) contract. The $1,408,956.00 task order was awarded to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a not-for-profit contract research organization, to perform detection and characterization of DNA adducts generated by tobacco flavorants in aerosol...
- This is a sole source, firm fixed-price contract awarded by the Food and Drug Administration (FDA) to the Lovelace Biomedical Research Institute, a not-for-profit contract research organization located in Albuquerque, New Mexico. The 24-month contract, valued at $7,058,881.75, is for the completion of toxicological studies for the FDA's Center for Tobacco Products. The award is not set aside for any small business category. Lovelace Biomedical Research Institute has significant experience...
- This is a delivery order contract awarded by the Food and Drug Administration (FDA) to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a non-profit research organization, to develop a standard guideline protocol for rodent tobacco smoke inhalation studies. The contract has a ceiling value of $1,373,599.00 and is a firm fixed-price task order issued under the "In Vivo Toxicology of Tobacco 2015-2020" indefinite-delivery, indefinite-quantity (IDIQ) contract. The...
- This is a firm fixed-price delivery order awarded by the Department of Health and Human Services Food and Drug Administration to Lovelace Biomedical Research Institute, a not-for-profit contract research organization. The contract has a potential value of $1,835,595.00 and is for a study to investigate the subjective effects and nicotine pharmacokinetics of mentholated smokeless tobacco products in current users. The contract is part of a larger Tobacco Products Pharmacology Study indefinite...
- This federal contract award, valued at $1,403,705.20, was issued by the Food and Drug Administration (FDA) to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a subsidiary of Lovelace Biomedical Research Institute. The contract is a delivery order issued under the Tobacco Products Pharmacology Study master indefinite-delivery, indefinite-quantity (IDIQ) contract vehicle. The contract does not have a set-aside designation. LBERI, a non-profit contract research organization,...
- The Food and Drug Administration (FDA) awarded a $46,048,623.38 firm fixed-price contract to the Lovelace Biomedical Research Institute to conduct a study on the toxicity of e-cigarette aerosols in in vivo nonclinical models. This contract, which does not have a set-aside designation, supports the FDA's Center for Tobacco Products (CTP) in evaluating e-cigarette products. Lovelace Biomedical Research Institute is a not-for-profit preclinical contract research organization that provides...
- This is a firm-fixed-price delivery order contract awarded by the Food and Drug Administration (FDA) to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI) for $679,680.00. The contract is part of a larger In Vivo Toxicology of Tobacco 2015-2020 Indefinite Delivery, Indefinite Quantity (IDIQ) contract. Under this task order, LBERI will conduct an assessment of tobacco products and tobacco product constituents' genetic toxicology using in vitro assays to compare the...
- This is a firm-fixed-price delivery order awarded by the Food and Drug Administration (FDA) to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a subsidiary of Lovelace Biomedical Research Institute. The $1,405,301.00 contract is for in vitro evaluation of the toxic profiles of tobacco additives using a systematic tiered approach. It is part of the larger "In Vivo Toxicology of Tobacco 2015-2020" indefinite delivery, indefinite quantity (IDIQ) contract vehicle....